Systemic treatment of malignant thymoma: A decade experience at a single institution

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 4, 2006, Pages 336-344

  Giaccone, Giuseppe ^a   Wilmink, Hanneke ^a   Paul, Marinus A ^a   Van Der Valk, Paul ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Targeted therapy; Thymoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; OCTREOTIDE; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SU 14813; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MYASTHENIA GRAVIS; PERITONEUM METASTASIS; PLEURA METASTASIS; POSITRON EMISSION TOMOGRAPHY; RARE DISEASE; RETROSPECTIVE STUDY; REVIEW; SEPSIS; STERNOTOMY; THORACOTOMY; THROMBOCYTOPENIA; THYMOMA; ADJUVANT THERAPY; ARTICLE; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMOMA; THYMUS NEOPLASMS;

EID: 33746787797     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000227481.36109.e7     Document Type: Review

References (36)

1. Takeda S, Miyoshi S, Akashi A, et al. Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution. J Surg Oncol. 2003;83:24-30.
2. Schmidt-Wolf IG, Rockstroh JK, Schuller H, et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol. 2003;82:69-76.
3. Rosai J. Histological Typing of Tumors of the Thymus, 2nd ed. New York: Springer-Verlag; 1999.
4. Maggi G, Giaccone G, Donadio M, et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer. 1986;58:765-776.
5. Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol. 1999;17:2280-2289.
6. Pollack A, Komaki R, Cox JD, et al. Thymoma: treatment and prognosis. Int J Radiat Oncol Biol Phys. 1992;23:1037-1043.
7. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105:546-551.
8. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003;76:1866-1872.
9. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol. 2005;17:140-146.
10. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer. 1996;73:882-886.
11. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093-3099.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
13. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010-2015.
14. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68:30-33.
15. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293-299.
16. Johnson SB, Eng TY, Giaccone G, et al. Thymoma: update for the new millennium. Oncologist. 2001;6:239-246.
17. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:814-820.
18. Giaccone G, Musella R, Bertetto O, et al. Cisplatin-containing chemotherapy in the treatment of invasive thymoma: report of five cases. Cancer Treat Rep. 1985;69:695-697.
19. Chahinian AP. Chemotherapy of thymomas and thymic carcinomas. Chest Surg Clin North Am. 2001;11:447-456.
20. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12:1164-1168.
21. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys. 2004;59:654-664.
22. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44:369-379.
23. Chalabreysse L, Etienne-Mastroianni B, Adeleine P, et al. Thymic carcinoma: a clinicopathological and immunohistological study of 19 cases. Histopathology. 2004;44:367-374.
24. Kitami A, Suzuki T, Kamio Y, et al. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol. 2001;31:601-604.
25. Tseng YL, Wang ST, Wu MH, et al. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg. 2003;76:1041-1045.
26. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76:878-884.
27. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol. 2004;27:68-72.
28. Lucchi M, Mussi A, Ambrogi M, et al. Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol. 2001;27:636-640.
29. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopathologic study based on the new World Health Organization classification. J Thorac Cardiovasc Surg. 2003;126:1134-1140.
30. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000;157:257-266.
31. Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002;94:1414-1420.
32. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004;130:222-224.
33. Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest. 2005;128:140-144.
34. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350:2625-2626.
35. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004;202:375-381.
36. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492.